Study shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
Global biopharma company GSK invests up to \u00a350 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.
A new blood test \u2013 powered by machine learning \u2013 has shown real promise in detecting multiple types of cancer in their earliest stages, when the disease is hardest to detect. Developed by a team of researchers and co-lead by the Centre for Human Genetics\u2019 Dr Dimitris Vavoulis, the test accurately detected six cancer types and could distinguish between people with and without cancer.
A new study led by Professor Ignacio Melero of NDM's Centre for Immuno-oncology and the University of Navarra and has highlighted a way to combat resistance to cancer immunotherapy in solid tumours by using antibodies that target GDF-15 protein.
RDM researchers have outlined the potential benefits and limitations of new spatial transcriptomic technologies for mapping the bone marrow in patients with blood cancer.
Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease \u2013 the first inoculation to do so.
An injection given during some asthma and chronic obstructive pulmonary disease (COPD) attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30 percent.
Using antibody data and mathematical modelling, a new study from researchers at the Pandemic Sciences Institute estimates annual patterns of influenza infection and protection over the past fifty years.
In a world first, researchers at the Kennedy Institute of Rheumatology and the Nuffield Department of Medicine have mapped the cellular dynamics following treatment with the most commonly used advanced therapy in autoimmune diseases. They have discovered why some patients benefit from this therapy while others do not, potentially paving the way for new therapies.
Researchers at the MRC WIMM have been awarded up to \u00a3600,000 from Cancer Research UK (CRUK) to create the world\u2019s first vaccine to prevent ovarian cancer.
High levels of acceptability for a point-of-care testing service to improve antibiotic distribution for in Vietnamese pharmacies have been discovered by the Oxford University Clinical Research Unit (OUCRU), part of the Nuffield Department of Medicine.
Researchers in the Nuffield Department of Medicine, supported by NIHR Oxford Biomedical Research Centre (BRC), have discovered a link between potentially pathogenic bacteria and airways inflammation in people with severe asthma.
Scientists from the Centre for Human Genetics at Nuffield Department of Medicine are taking the initial steps in developing the UK\u2019s first vaccine to prevent cancer in people with Lynch syndrome, thanks to funding from Cancer Research UK.
The Van den Eynde groups at the Ludwig Institute for Cancer Research in Brussels and Oxford have demonstrated that deletion of PHD2/3 enzymes in CD8 T cells shows an enhanced tumour response in various cancer models.
Researchers at the University of Oxford and the University of Liverpool have for the first time been able to estimate the current burden of Lassa fever, project the impacts of a Lassa fever vaccination programme, and demonstrate how it may help avoid the next pandemic.
The Faculty of Medicine Universitas Indonesia (FMUI) and OUCRU Indonesia have completed a phase 2 clinical trial for two new malaria vaccines developed by Sanaria Inc. This is the first malaria vaccine trial ever conducted in Indonesia and the first in the Asia-Pacific region in over 30 years.
![\"The](\"https://www.immunology.ox.ac.uk/news/pancreatic-cancer-immune-map-provides-clues-for-precision-treatment-targeting-1/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n